Verve Therapeutics Inc (VERV) — Cash Flow-to-Debt Ratio
Latest as of March 2025:
-0.20x
Verve Therapeutics Inc (VERV) has a Cash Flow-to-Debt Ratio of -0.20x as of March 2025, meaning its operating cash flow of $-27.84 Million could theoretically repay 0% of its total liabilities ($140.65 Million) in one year. See how financially flexible is Verve Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.20x
Operating CF / Total Liabilities
Operating Cash Flow
$-27.84 Million
USD
Total Liabilities
$140.65 Million
USD
Data as of
Mar 2025
Most recent filing
Verve Therapeutics Inc Cash Flow-to-Debt Ratio (2019–2024)
Historical debt coverage capacity for Verve Therapeutics Inc across 6 annual periods. For the full cash flow conversion analysis, see VERV cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Verve Therapeutics Inc (2019–2024)
Year-by-year debt coverage analysis for Verve Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.02x | $-157.69 Million | $153.99 Million | ▼ -4.9% |
| 2023 | -0.98x | $-149.55 Million | $153.19 Million | ▼ -2.4% |
| 2022 | -0.95x | $-122.33 Million | $128.29 Million | ▲ +67.2% |
| 2021 | -2.91x | $-77.88 Million | $26.77 Million | ▼ -1074.0% |
| 2020 | -0.25x | $-35.27 Million | $142.32 Million | ▼ -37.2% |
| 2019 | -0.18x | $-7.44 Million | $41.20 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.